Collectively, these findings support a chemoattractant mechanism for the sustained clinical response to pembrolizumab therapy observed in CTCL responders: upregulation of CXCL13 in tumor cells attracts effector PD-1+ CD4+ T cells, promoting successful antitumor activity. Here, CXCL13 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.